🟢 SAB Biotherapeutics is trading 10.75% up in pre-market

SAB Biotherapeutics is trading at $3.40, up 10.75% in pre-market, with no clear company-specific catalyst identified for October 28.

• The latest company-specific development found was the FDA Fast Track designation for SAB-142, announced October 13; it is prior news, not a confirmed trigger for the move.
• A recent report highlighted diabetes-trial progress, but did not establish a connection to the gain.
• Supplied broad-market indicators are mixed and modest and do not clearly explain the move.